Time to Reconsider Biospecifics Technologies Corp (NASDAQ:BSTC) After Less Short Sellers?

June 23, 2018 - By Kenneth Lin

Investors sentiment decreased to 0.77 in 2018 Q1. Its down 0.45, from 1.22 in 2017Q4. It is negative, as 14 investors sold BioSpecifics Technologies Corp. shares while 29 reduced holdings. 12 funds opened positions while 21 raised stakes. 3.50 million shares or 3.69% less from 3.63 million shares in 2017Q4 were reported.
Smith Asset Lp accumulated 6,117 shares. The New York-based Renaissance Technologies has invested 0.02% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Denali Advisors Lc invested in 0% or 55 shares. Financial Architects Inc holds 0% or 360 shares. Meeder Asset Mngmt Incorporated invested in 0% or 988 shares. Employees Retirement Of Ohio reported 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Legal & General Gru Plc has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Rhumbline Advisers accumulated 4,983 shares or 0% of the stock. Parametric Associates Ltd Liability Com invested in 0% or 9,335 shares. Elk Creek Ltd Co holds 0.43% or 165,085 shares in its portfolio. Us Savings Bank De stated it has 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Matarin Management Limited Liability Company reported 33,780 shares. Prudential Fincl Incorporated reported 73,192 shares stake. First Quadrant Ltd Partnership Ca owns 6,715 shares or 0.01% of their US portfolio. Geode Cap Lc reported 58,791 shares or 0% of all its holdings.

The stock of Biospecifics Technologies Corp (NASDAQ:BSTC) registered a decrease of 4.26% in short interest. BSTC’s total short interest was 168,500 shares in June as published by FINRA. Its down 4.26% from 176,000 shares, reported previously. With 16,900 shares average volume, it will take short sellers 10 days to cover their BSTC’s short positions. The short interest to Biospecifics Technologies Corp’s float is 3.11%.

The stock increased 4.80% or $2.01 during the last trading session, reaching $43.91. About 57,159 shares traded or 166.92% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has declined 16.75% since June 23, 2017 and is downtrending. It has underperformed by 29.32% the S&P500.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $316.78 million. The firm offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 26.94 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

Another recent and important BioSpecifics Technologies Corp. (NASDAQ:BSTC) news was published by Globenewswire.com which published an article titled: “Investor Expectations to Drive Momentum within Capital Product Partners, Nova Measuring Instruments, BioSpecifics …” on June 06, 2018.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: